Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: A cautionary note

Journal of Neurology Neurosurgery and Psychiatry

Volumn 65, Issue 5, 1998, Pages 774-777

  Graham, Jacqueline M ^a   Sussman, Jon D ^a   Ford, Kay S ^a   Sagar, Harvey J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Hallucinosis; Olanzapine; Parkinson's disease

Indexed keywords

OLANZAPINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HALLUCINOSIS; HUMAN; MALE; MOTOR DYSFUNCTION; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0031733612     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.65.5.774     Document Type: Article

References (7)

1. Moskovitz C, Moses H, Klawans HL. Levodopa-induced psychosis: A kindling phenomenon. Am J Psychiatry 1978;135:669-75.
2. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1978;192: 481-3.
3. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-24.
4. Wolters ECh, Jansen ENH, Tuynman-Qua H, et al. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996;47:1085-7.
5. Daniel SE, Lees AJ. Parkinson's Disease Society brain bank, London: overview and research. J Neural Transm 1993; 39(suppl):165-72.
6. Fahn S, Elton RL, members of the UPDRS Development Committee. The unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, et al, eds. Recent developments in Parkinson's disease. Vol 2. Florham Park, NJ: Macmillan Healthcare Information, 1987:153-163, 293-304.
7. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-42.